Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings
10.2.2025 07:50:00 CET | ACCESS Newswire | Press release
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence.
"The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. History now repeats itself, except now the anti-vaccine lawyer, Kennedy, could become in charge of US science and medicine as a whole."
Eviva Partners's solution to this crisis is simple: "Evidence Fluency." The premise is that one key, previously overlooked factor underlies the current challenges of poor and unequal outcomes and rising costs in the U.S. healthcare system: insufficient "evidence fluency" among patients, providers, and other healthcare stakeholders.
"We are a nonpartisan organization committed to helping improve health outcomes for all" said Morozov.
Eviva Partners introduces the concept of "evidence fluency" as a solution to the current crisis and a path towards improving healthcare overall, defined as having four components:
Understanding the concept of evidence as distinct from "proof;"
Ability to assess the strength of evidence;
Ability to detect manipulation;
Ability to discuss evidence with others.
Eviva Partners will focus on three areas:
Pioneering deep characterization of care gaps (both underuse and overuse), starting in hematology-oncology care, at the state level;
Developing a multi-pronged approach to increase evidence fluency through:
"Two-Eyed Seeing" methodology for bridging worldviews
K-12 evidence curriculum
A tool kit for patients and providers
Creating state and federal policy proposals to improve healthcare transparency and quality, starting with protecting the integrity of scientific literature.
The organization has assembled a distinguished advisory council including Elder Albert Marshall of the Mi'kmaw Nation, creator of the "Two-Eyed Seeing" methodology; Stephan Lewandowsky, a leading cognitive scientist at the University of Bristol, and others.
"Our preliminary surveys show that only 16% of U.S. adults correctly understand the difference between evidence and proof, while 36% have never heard the word 'evidence' used in a medical context," said Morozov. "By improving evidence fluency across the healthcare ecosystem, we can help close care gaps and ultimately improve health outcomes for all."
Initial pilot studies will focus on sickle cell disease and cancer, where care gaps are high. In addition, K-12 evidence curriculum will be piloted. Once those are completed, the organization plans to launch a nationwide public awareness campaign to promote evidence fluency.
For more information about Eviva Partners, and to read Alex Morozov's expose, "Robert F. Kennedy Jr, Andrew Wakefield and The Manufacture of Evidence," visit www.evivapartners.org, or follow Eviva Partners on Twitter, BlueSky, LinkedIn, Facebook and Instagram.
Contact Information
Alex Morozov
CEO and Founder
alex.morozov@evivapartners.org
9173751112
SOURCE: Eviva Partners
View the original press release on ACCESS Newswire
Eviva Partners

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra Appoints Matt Borowiec as Chief Commercial Officer1.5.2026 15:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / May 1, 2026 / Formerra, a leading distributor of performance materials, today announced the appointment of Matt Borowiec as Chief Commercial Officer (CCO). Borowiec will lead the company's commercial organization to support continued growth and global expansion while strengthening sales execution and customer success. Borowiec is a seasoned executive with over 25 years' experience in operations, commercial and P&L roles across resin manufacturing, specialty compounding, and distribution, including leadership roles at GE Plastics, PolyOne (now Avient), Transcendia, Celanese, and Kinsley Group. With this background, he is well positioned to lead Formerra's commercial strategy at this important time in the company's evolution. "Matt brings a unique combination of producer‑side and distribution experience that positions him well to strengthen alignment between our suppliers, customers, and commercial teams," said Tom Kelly, Chief Executive Officer at Forme
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release
INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu
Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions1.5.2026 14:00:00 CEST | Press release
Strategic acquisition is anticipated to position Datavault AI to bring CyberCatch's AI-enabled cyber risk mitigation solution into Datavault AI's SanQtum-secured edge Graphics Processing Unit ecosystem, addressing a global information security market projected to reach $240 billion in 2026 (Gartner) CyberCatch's post-quantum cryptography conversion plan is also expected to position the combined company ahead of the AI-enabled "Q-Day" quantum-attack horizon, now compressed to as early as 2029 (Google) AI-enabled adversary attacks in 2025 rose 89% year-over-year while average eCrime breakout time fell to 29 minutes, a 65% increase in adversary speed compared to 2024, per CrowdStrike's 2026 Global Threat Report, and Google Quantum AI research has now compressed the timeline for cryptographically relevant quantum computing to as early as 2029. PHILADELPHIA, PA AND SAN DIEGO, CA / ACCESS Newswire / May 1, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider o
Securitas Healthcare Acquires ZulaFly(TM) to Advance Cloud-Based RTLS and Accelerate Innovation Across Healthcare1.5.2026 14:00:00 CEST | Press release
LINCOLN, NE / ACCESS Newswire / May 1, 2026 / Securitas Healthcare, a leading provider of real‑time visibility and protection solutions for the healthcare industry, is proud to announce the acquisition of ZulaFly, a healthcare‑focused Real‑Time Location System (RTLS) and staff safety technology company known for its modern, cloud‑based platform. ZulaFly's cloud-based RTLS platform delivers real-time visibility and actionable insights through a flexible, data-driven architecture. Built as a single SOC 2 Type II-compliant instance, ZulaFly offers an intuitive user experience, easy configuration, standardized data models, centralized analytics, and simplified system management. This approach enables healthcare organizations to deploy faster, gain insights sooner, and reduce long-term total cost of ownership (TCO). "This acquisition aligns with our focus and commitment to delivering best‑in‑class RTLS solutions across both cloud-based and on-premise options, keeping our healthcare clients
Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 202630.4.2026 21:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / April 30, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset ("RWA") tokenization technologies, today announced that it will report financial results for its first quarter of 2026 prior to market open on Friday, May 15, 2026. Following the release, Datavault AI will host a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Friday, May 15, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-709-8150 Participant Dial-in (International): 1-201-689-8354 -- or Click HERE for participant International Toll-Free access numbers Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here About Datavau
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom